KYKOF - Kyowa Kirin wins European nod for self-administered CRYSVITA

Kyowa Kirin (KYKOF) announced that the European Medicines Agency ((EMA)) has recommended the self-administration option of CRYSVITA (burosumab) for the treatment of X-linked hypophosphataemia ((XLH)).The decision by the Committee for Medicinal Products for Human Use ((CHMP)) of EMA will pave the way for the European Commission to grant the approval for CRYSVITA to be administered by certain patients or caregivers at the recommendation of a physician.Kyowa Kirin and Ultragenyx Pharmaceutical (RARE) has a partnership to develop and commercialize CRYSVITA globally.In 2020, subcutaneously administered CRYSVITA received the European authorization to XLH, a rare metabolic bone disease affecting children and adults.In December 2019, Royalty Pharma (RPRX) acquired the rights to receive Ultragenyx’s royalty payments linked to CRYSVITA sales in Europe.

For further details see:

Kyowa Kirin wins European nod for self-administered CRYSVITA